Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey.
Gizem AyanSinem Nihal EsatogluGülen HatemiSinem Nihal EsatogluPublished in: Rheumatology international (2020)
The objective of the study is to assess the disease course and associated healthcare costs in a cohort of established rheumatoid arthritis (RA) patients in Turkey. The study cohort consisted of 75 RA patients from our outpatient clinic who took part in a previous multicenter study assessing RA-related healthcare costs 6 years ago. In March 2018, we attempted to re-evaluate these patients with the same questionnaire of the previous study enabling us to get information on medication use, comorbidities, and RA-related healthcare costs. We used RAPID-3 for assessing disease activity, HAQ-DI for functional status and EQ-5D for quality of life. Sixty-two (83%) patients were re-evaluated, seven (9.3%) had died and three (4%) were receiving palliative care following major cardiovascular events. Forty-seven (76%) patients had used at least one biologic agent during 79.1 ± 3.3 months after the previous study. At the last evaluation, 34 patients (55%) were on biologics, 22 (35%) were on csDMARDs and 6 (9.6%) were off RA treatment. The mean RAPID3 score (4.3 ± 1.6 SD) was similar to that of the previous study. HAQ-DI (0.69 ± 0.57 SD) and EQ-5D (0.68 ± 0.21 SD) scores showed significant improvement over time. Median direct costs (€2998) were higher than indirect costs (€304). Medication costs were high (€2958). Disease activity remained stable, while functional status and QoL had improved over time. Serious infections and cardiovascular disability are a concern. Medication costs are still the main determinant of RA-related healthcare costs.
Keyphrases
- rheumatoid arthritis
- disease activity
- healthcare
- end stage renal disease
- rheumatoid arthritis patients
- newly diagnosed
- ejection fraction
- systemic lupus erythematosus
- chronic kidney disease
- palliative care
- ankylosing spondylitis
- cardiovascular events
- prognostic factors
- escherichia coli
- emergency department
- multiple sclerosis
- cardiovascular disease
- patient reported outcomes
- interstitial lung disease
- quantum dots
- candida albicans
- drug induced
- smoking cessation
- combination therapy